THE PRESIDENTIAL Commission on the Human Immunodeficiency Virus Epidemic is sending its final report to the White House this week.
Earlier, it sent an interim report that dealt with three areas of the epidemic: intravenous drug abuse, patient care, and research and drug development (JAMA 1988;259:2195-2199). This week's report deals with the remaining topics of its charge: incidence and prevalence of acquired immunodeficiency syndrome in the United States; prevention and education; discrimination; ethics; testing; confidentiality; safety of the blood supply and in the workplace; social and legal issues; the financing of patient care; and international concerns. A month from now, under terms of the executive order that created it a year ago, the commission will be terminated.
It is possible that some members of the commission might disagree sufficiently with the final recommendations and conclusions of the majority to issue a minority report. Asked about this, a commission staff member